Preoperative detection of hepatic venous collaterals in right liver graft
Shoichi Satou, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi – 24 May 2005
Cryopreserved iliac artery is indispensable interposition graft material for middle hepatic vein reconstruction of right liver grafts
Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Kwang‐Min Park, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha – 24 May 2005 – Cryopreserved iliac vein grafts (IVGs) have often been used for reconstruction of middle hepatic vein (MHV) branches in right liver grafts, but their storage pool has often been exhausted in our institution due to the low incidence of deceased donor organ procurement. To overcome this shortage of IVG, we started to use cryopreserved iliac artery graft (IAG).
Which is the holy grail in liver transplantation: Hyponatremia, MELD, or a combination?
Teh‐Ia Huo, Shou‐Dong Lee, Jaw‐Ching Wu – 24 May 2005
Ribavirin mutagenesis: Hidden clues in mathematical models
Zhi Hong – 24 May 2005
Fulminant hepatic failure
David A. Sass, A. Obaid Shakil – 24 May 2005
Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non‐heart beating donor
Olivier Detry, Arnaud De Roover, Laurence de Leval, Christian Herens, Jean Delwaide, Pierre Honoré, Michel Meurisse – 24 May 2005 – Transmission of an undiagnosed cancer with solid organ transplantation is a rare but dreadful event. In this paper the authors report the transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a Maastricht category 3 non‐heart beating donor. To the authors' knowledge this case is the first report of such a transmission with a liver graft procured in a non‐heart beating donor.
Progress toward the therapy of hepatitis with RNAi
Glenn Rendall – 24 May 2005
Adjuvant iodine‐131‐labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: Which is the best treatment schedule?
Marco Tabone, Luca Vigano, Cristiana Laudi, Alessandro Ferrero, Riccardo Pellerito, Lorenzo Capussotti – 23 May 2005
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
David V. Morrissey, Karin Blanchard, Lucinda Shaw, Kristi Jensen, Jennifer A. Lockridge, Brent Dickinson, James A. McSwiggen, Chandra Vargeese, Keith Bowman, Chris S. Shaffer, Barry A. Polisky, Shawn Zinnen – 23 May 2005 – To develop synthetic short interfering RNA (siRNA) molecules as therapeutic agents for systemic administration in vivo, chemical modifications were introduced into siRNAs targeted to conserved sites in hepatitis B virus (HBV) RNA. These modifications conferred significantly prolonged stability in human serum compared with unmodified siRNAs.